title: Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.
abstract: The family of JAK comprises four members and has received significant attention in recent years from the pharmaceutical industry as a therapeutic target. The role of JAK is central to cytokine signaling pathways. It is believed that selective modulation of one specific JAK can lead to the inhibition of a restricted set of cytokines, which should avoid undesired side effects and get closer to the profile of biologic therapies. Consequently, selective JAK inhibition has become a major focus area of drug discovery research. A review of the TYK2 patents indicates that industry attention has recently turned toward the development of specific inhibitors. Importantly, despite the increasing number of published patents, none of these drugs have yet made it to the clinical trials.
authors.forename: Christel J
authors.initials: CJ
authors.lastname: Menet
mesh_terms: D002986:Clinical Trials as Topic; D007249:Inflammation / Q000188:drug therapy*; D053612:Janus Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000502:physiology*; D010330:Patents as Topic; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D011725:Pyridines; D011743:Pyrimidines; D053634:TYK2 Kinase / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011743:Pyrimidines; D053612:Janus Kinases; D053634:TYK2 Kinase